Background: Individual adaptation of processed patient's blood volume (PBV) should reduce number and/or duration of autologous peripheral blood progenitor cell (PBPC) collections.
Study Design And Methods: The durations of leukapheresis procedures were adapted by means of an interim analysis of harvested CD34+ cells to obtain the intended yield of CD34+ within as few and/or short as possible leukapheresis procedures. Absolute efficiency (AE; CD34+/kg body weight) and relative efficiency (RE; total CD34+ yield of single apheresis/total number of preapheresis CD34+) were calculated, assuming an intraapheresis recruitment if RE was greater than 1, and a yield prediction models for adults was generated.
Results: A total of 196 adults required a total of 266 PBPC collections. The median AE was 7.99 x 10(6), and the median RE was 1.76. The prediction model for AE showed a satisfactory predictive value for preapheresis CD34+ only. The prediction model for RE also showed a low predictive value (R2 = 0.36). Twenty-eight children underwent 44 PBPC collections. The median AE was 12.13 x 10(6), and the median RE was 1.62. Major complications comprised bleeding episodes related to central venous catheters (n = 4) and severe thrombocytopenia of less than 10 x 10(9) per L (n = 16).
Conclusion: A CD34+ interim analysis is a suitable tool for individual adaptation of the duration of leukapheresis. During leukapheresis, a substantial recruitment of CD34+ was observed, resulting in a RE of greater than 1 in more than 75 percent of patients. The upper limit of processed PBV showing an intraapheresis CD34+ recruitment is higher than in a standard large-volume leukapheresis. Therefore, a reduction of individually needed PBPC collections by means of a further escalation of the processed PBV seems possible.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1537-2995.2006.00910.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Efficacy and safety of first-line treatment with anti-CD38 monoclonal antibody-based regimen for primary plasma cell leukemia].
Zhonghua Yi Xue Za Zhi
February 2024
Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
To analyze the efficacy and safety of first-line treatment with an anti-CD38 monoclonal antibody regimen for primary plasma cell leukemia (pPCL). Patients diagnosed with pPCL from December 1, 2018 to July 26, 2023, receiving first-line treatment of anti-CD38 monoclonal antibody-based regimens across multiple centers including Peking University People's Hospital, Fuxing Hospital of Capital Medical University, Qingdao Municipal Hospital, Shengjing Hospital of China Medical University, Handan Central Hospital, the First Affiliated Hospital of Harbin Medical University, the Fourth Hospital of Hebei Medical University and General Hospital of Ningxia Medical University were consecutively included. A total of 24 pPCL patients were included with thirteen being male and eleven being female.
View Article and Find Full Text PDFRadiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma.
Transplant Cell Ther
January 2023
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Article Synopsis
- The study looked at how radiation therapy (RT) affects collecting certain blood cells from patients with multiple myeloma (MM) who need a stem cell transplant.
- Researchers reviewed medical records of 732 patients who underwent RT between 1999 and 2017, focusing on 223 of them who had RT before collecting blood cells for the transplant.
- They found that the amount of bone marrow treated with RT and the radiation dose didn't seem to impact the number of blood cells that could be collected for the transplant.
Adverse events related to central venous catheters (CVC) and the influence of CVC characteristics on peripheral blood hematopoietic progenitor cell collection in children.
Front Pediatr
April 2023
Hematology and Hemotherapy Unit, Fundación para la Investigación Biomédica Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
Introduction: The use of peripheral blood progenitor cells (PBPCs) as a source for hematopoietic stem cell transplantation (HSCT) in pediatric healthy donors is still under debate. The risk of a central venous catheter (CVC) placement and catheter-related complications continue to be the main arguments to discourage its use.
Methods: we present a retrospective analysis of 140 PBPC collections in pediatric patients and donors, describing adverse events (AE) related to CVCs as well as the influence of catheterrelated variables on the efficiency of the leukapheresis.
Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study.
Blood Adv
April 2023
Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Article Synopsis
- Inadequate mobilization of peripheral blood progenitor cells (PBPCs) hampers the success of autologous hematopoietic cell transplantation (auto-HCT), and the study focuses on how clonal hematopoiesis (CH) affects this mobilization.
- The research examined 776 patients, identifying 90 poor mobilizers and 89 controls, revealing that CH was present in 27% of patients, but did not significantly correlate with mobilization failure.
- Notably, mutations in PPM1D and TP53 were more common in poor mobilizers, with a higher incidence of therapy-related myeloid neoplasms (t-MN) in this group, highlighting the need to further explore their
[The Role and Mechanism of Tfh and B Cell in Human Chronic Graft-Versus-Host-Disease].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
April 2022
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215006, Jiangsu Province, China,E-mail:
Article Synopsis
- The study aimed to explore the role of different immune cell types, specifically circulating follicular helper T cells (cTfh), extrafollicular helper T cells, and B cells, in chronic graft-versus-host disease (cGVHD) following stem cell transplantation.
- It was found that patients with cGVHD had significantly decreased levels of cTfh cells and increased levels of extrafollicular helper T cells compared to healthy donors, indicating a shift in immune response.
- Additionally, there were notable changes in B cell subsets, with higher percentages of antigen-stimulated B cells and a reduction in naive B cells, suggesting an altered immune landscape in cGVHD patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!